Chemotherapy response rate in seminoma and non-seminoma testicular cancer cases

Radian Dwi Desianto; Suharto Wijanarko; Joko Purnomo; Nasrul An Nafiq

doi:10.18203/2349-2902.isj20261986

Authors

Radian Dwi Desianto General Surgery Residency Program, Faculty of Medicine, University Sebelas Maret, Surakarta, Central Java, Indonesia https://orcid.org/0009-0006-3893-3641
Suharto Wijanarko Department of Surgery, Faculty of Medicine, University Sebelas Maret/ General Hospital Dr. Moewardi, Surakarta, Central Java, Indonesia
Joko Purnomo Department of Surgery, Faculty of Medicine, University Sebelas Maret/ General Hospital Dr. Moewardi, Surakarta, Central Java, Indonesia
Nasrul An Nafiq General Surgery Residency Program, Faculty of Medicine, University Sebelas Maret, Surakarta, Central Java, Indonesia https://orcid.org/0009-0009-7963-0745

DOI:

https://doi.org/10.18203/2349-2902.isj20261986

Keywords:

Chemotherapy, Tumor markers, Testicular cancer

Abstract

Background: Testicular cancer is a malignancy in the form of a solid tumor that occurs in men, with a global prevalence that has been steadily increasing. The most commonly found types are seminoma and non-seminoma, particularly among individuals aged 20-34 years. In recent decades, 9,560 new cases of testicular cancer were recorded in the United States in 2019. In Indonesia, based on data from January 1995 to December 2004, the majority of testicular cancer cases were also seminoma and non-seminoma types, with patient ages ranging from 18 to 72 years.

Methods: Data analysis was performed using SPSS software version 29.0, employing univariate and bivariate analyses. Univariate analysis was used to describe the characteristics of the study samples. Ratio-scale data were described using the mean as a measure of central tendency and standard deviation (SD) as a measure of dispersion. Categorical data were described in percentages (%) and numbers (n), and presented in tables. Differences in chemotherapy response outcomes among testicular cancer patients, which are categorical data, were analyzed using bivariate analysis. Comparative tests were conducted to assess differences in the success rates of chemotherapy responses in testicular cancer patients. Both tests were considered statistically significant if they had a p<0.05.

Results: Complete chemotherapy response in seminoma and non-seminoma testicular cancer was nearly similar at 66.7% and 68.8%, respectively; partial chemotherapy responses in seminoma and non-seminoma were 13.3% and 18.8%; however, progressive chemotherapy responses tended to be higher in seminoma (20.0%) than in non-seminoma (12.5%).

Conclusions: The success rate of chemotherapy response in testicular cancer cases was mostly complete (67.7%), while partial and progressive responses were 16.1% each, and there was no difference in chemotherapy response between seminoma and non-seminoma tumors.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

Park JS, Kim J, Elghiaty A, Ham WS. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore). 2018;97(37):e12390.

Suprabawati T, Umbas R. Karakteristik dan faktor-faktor prediktif pada tumor testis dewasa di Jakarta. J Urol Indones. 2007;3:92-95.

Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors. J Cell Physiol. 2013;228(8):1641-6.

Sheikine Y, Genega E, Melamed J, Lee P, Reuter V, Ye H. Molecular genetics of testicular germ cell tumors.

Litchfield K, Levy M, Huddart R, Shipley J, Turnbull C. Large-scale sequencing of testicular germ cell tumour cases excludes major TGCT predisposition gene. Eur Urol. 2018;73(6):828-31.

Stephenson A, Eggener SE, Bass EB. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019;202(2):272-81.

Culine S, Kerbrat P, Kramar A. Randomized trial comparing BEP with alternating regimens in metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2008;26(3):421-7.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.

Schwartz LH, Litiere S, de Vries E, Robert F, Stephen G, Sumithra M, et al. RECIST 1.1 update and clarification. Eur J Cancer. 2016;62:132-7.

Oldenburg J, Fossa SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines. Ann Oncol. 2013;24(6):vi125-32.

Albers P, Albrecht W, Algaba F, Carsten B, Gabriella CC, Karim F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054-68.

Cheng L, Zhang S, MacLennan GT, Stephen DWB, Richard SF, Mingsheng W, Thomas MU, et al. Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. Mod Pathol. 2012;25(10):1432-8.

Albany C, Kesler K, Cary C. Management of residual mass in germ cell tumors after chemotherapy. Curr Oncol Rep. 2019;21(1):5.

Grogg JB, Schneider K, Bode PK. Risk factors and treatment outcomes of testicular granulosa cell tumors. J Cancer Res Clin Oncol. 2020;146(11):2829-41.

Ostertagova E, Ostertag O, Kovac J. Methodology and application of one-way ANOVA. Am J Mech Eng. 2014;2(7):256-61.

Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763-8.

Gaddam S, Chestnut G. Testicle cancer. StatPearls. 2022.

Lamichhane A, Mukkamalla SKR. Seminoma. StatPearls. 2023.

Nauman M, Leslie WS. Nonseminomatous testicular tumors. StatPearls. 2023.

McGlynn KA, Devesa SS, Graubard BI, Castle PE. Trends in the incidence of testicular germ cell tumors in the United States. Cancer. 2003;97(1):63-70.

Fabrianta DM, Seputra KP, Daryanto B. Characteristic chemotherapy response of testicular cancer patients in tertiary hospital. Indones J Urol. 2022;29(3):208-11.

Nugroho A, Renaldo J, Djatisoesanto W. Correlations between staging and chemotherapy response with testicular carcinoma non-seminoma. Folia Med Indones. 2021;56(3):178.

Voutsadakis IA. The chemosensitivity of testicular germ cell tumors. Cell Oncol. 2014;37(2):79-94.